Your browser doesn't support javascript.
Manufacturing a chimpanzee adenovirus-vectored SARS-CoV-2 vaccine to meet global needs.
Joe, Carina C D; Jiang, Jinlin; Linke, Thomas; Li, Yuanyuan; Fedosyuk, Sofiya; Gupta, Gaurav; Berg, Adam; Segireddy, Rameswara R; Mainwaring, David; Joshi, Amar; Cashen, Paul; Rees, Byron; Chopra, Nitin; Nestola, Piergiuseppe; Humphreys, Jonathan; Davies, Sarah; Smith, Nick; Bruce, Scott; Verbart, Dennis; Bormans, Daan; Knevelman, Carol; Woodyer, Mark; Davies, Lee; Cooper, Lisa; Kapanidou, Maria; Bleckwenn, Nicole; Pappas, Daniel; Lambe, Teresa; Smith, Daniel C; Green, Catherine M; Venkat, Raghavan; Ritchie, Adam J; Gilbert, Sarah C; Turner, Richard; Douglas, Alexander D.
  • Joe CCD; Nuffield Department of Medicine, Jenner Institute, University of Oxford, Oxford, UK.
  • Jiang J; Biopharmaceuticals Development, R&D, AstraZeneca, Gaithersburg, Maryland, USA.
  • Linke T; Biopharmaceuticals Development, R&D, AstraZeneca, Gaithersburg, Maryland, USA.
  • Li Y; Nuffield Department of Medicine, Jenner Institute, University of Oxford, Oxford, UK.
  • Fedosyuk S; Nuffield Department of Medicine, Jenner Institute, University of Oxford, Oxford, UK.
  • Gupta G; Nuffield Department of Medicine, Jenner Institute, University of Oxford, Oxford, UK.
  • Berg A; Nuffield Department of Medicine, Jenner Institute, University of Oxford, Oxford, UK.
  • Segireddy RR; Nuffield Department of Medicine, Jenner Institute, University of Oxford, Oxford, UK.
  • Mainwaring D; Pall Europe, Portsmouth, UK.
  • Joshi A; Pall Europe, Portsmouth, UK.
  • Cashen P; Pall Europe, Portsmouth, UK.
  • Rees B; Pall Europe, Portsmouth, UK.
  • Chopra N; Sartorius Stedim Biotech GmbH, Goettingen, Germany.
  • Nestola P; Sartorius Stedim Switzerland AG, Tagelswangen, Switzerland.
  • Humphreys J; Vaccine Manufacturing and Innovation Centre, Oxford, UK.
  • Davies S; Cobra Biologics, Keele, UK.
  • Smith N; Cobra Biologics, Keele, UK.
  • Bruce S; Cobra Biologics, Keele, UK.
  • Verbart D; Halix BV, Leiden, The Netherlands.
  • Bormans D; Halix BV, Leiden, The Netherlands.
  • Knevelman C; Oxford Biomedica PLC, Cowley, UK.
  • Woodyer M; Oxford Biomedica PLC, Cowley, UK.
  • Davies L; Oxford Biomedica PLC, Cowley, UK.
  • Cooper L; Oxford Biomedica PLC, Cowley, UK.
  • Kapanidou M; Oxford Biomedica PLC, Cowley, UK.
  • Bleckwenn N; Biopharmaceuticals Development, R&D, AstraZeneca, Gaithersburg, Maryland, USA.
  • Pappas D; Biopharmaceuticals Development, R&D, AstraZeneca, Gaithersburg, Maryland, USA.
  • Lambe T; Nuffield Department of Medicine, Jenner Institute, University of Oxford, Oxford, UK.
  • Smith DC; Cobra Biologics, Keele, UK.
  • Green CM; Clinical Biomanufacturing Facility, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Venkat R; Biopharmaceuticals Development, R&D, AstraZeneca, Gaithersburg, Maryland, USA.
  • Ritchie AJ; Nuffield Department of Medicine, Jenner Institute, University of Oxford, Oxford, UK.
  • Gilbert SC; Nuffield Department of Medicine, Jenner Institute, University of Oxford, Oxford, UK.
  • Turner R; Purification Process Sciences, Biopharmaceuticals Development, R&D, AstraZeneca, Cambridge, UK.
  • Douglas AD; Nuffield Department of Medicine, Jenner Institute, University of Oxford, Oxford, UK.
Biotechnol Bioeng ; 119(1): 48-58, 2022 01.
Article in English | MEDLINE | ID: covidwho-1441944
ABSTRACT
Manufacturing has been the key factor limiting rollout of vaccination during the COVID-19 pandemic, requiring rapid development and large-scale implementation of novel manufacturing technologies. ChAdOx1 nCoV-19 (AZD1222, Vaxzevria) is an efficacious vaccine against SARS-CoV-2, based upon an adenovirus vector. We describe the development of a process for the production of this vaccine and others based upon the same platform, including novel features to facilitate very large-scale production. We discuss the process economics and the "distributed manufacturing" approach we have taken to provide the vaccine at globally-relevant scale and with international security of supply. Together, these approaches have enabled the largest viral vector manufacturing campaign to date, providing a substantial proportion of global COVID-19 vaccine supply at low cost.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Drug Industry / COVID-19 Vaccines / COVID-19 / Vaccine Development / ChAdOx1 nCoV-19 Topics: Vaccines Limits: Animals / Humans Language: English Journal: Biotechnol Bioeng Year: 2022 Document Type: Article Affiliation country: Bit.27945

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Drug Industry / COVID-19 Vaccines / COVID-19 / Vaccine Development / ChAdOx1 nCoV-19 Topics: Vaccines Limits: Animals / Humans Language: English Journal: Biotechnol Bioeng Year: 2022 Document Type: Article Affiliation country: Bit.27945